Ulf Grawunder is a successful serial Biotech entrepreneur, who since 2004 has founded three Biotech companies, of which two have exited to other companies by trade-sale. In 2004 he co-founded the therapeutic antibody discovery company 4-Antibody in Basel, where he initially served as start-up CEO and later as CSO, until the company was sold to US-based Agenus Inc. In 2012 Ulf founded NBE-Therapeutics, active in the area of antibody-drug conjugates for cancer therapy. Ulf built NBE-Therapeutics from inception to the trade-sale of the company to Boehringer Ingelheim for US$ 1.4 billion in 2021. Since recently, Ulf is co-founder of T-CURX from Würzburg, Germany, developing CAR-T cell therapies for cancer patients.

A biochemist by training, Ulf received his PhD from the Basel Institute for Immunology. During his academic career he worked at Washington University School of Medicine (USA), the University of Southern California (USA) and the Basel Institute for Immunology. Ulf also holds a Diploma of Technology Entrepreneurship from the University St. Gallen.

Ulf is advisor and teaching faculty member of several institutions, including the iImmune elite master studies program (Erlangen, Germany), the Swiss Venturekick start-up program, the European Center for Pharmaceutical Medicine (Basel). Ulf also serves as Vice-president and Board member of the Swiss Biotech Association.